Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. CRISPR Therapeutics AG’s current trading price is 0.25% away from its 52-week high, while its distance from the 52-week low is 92.22%. The stock’s price range over this period has fluctuated between $37.55 and $72.00. The company, operating within the financial sector, had a trading volume of approximately 8.01 million for the day, which was noticeably higher than the average daily share volume of 1.5 million over the last 3 months.
The stock of CRISPR Therapeutics AG (CRSP) is currently priced at $72.18. In the last session, the stock climbed significantly, topping out at $76.19 after opening at $69.57. The day’s lowest price was $68.10 before the stock closed at $67.89.
CRISPR Therapeutics AG experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $72.00 on 11/20/23, while the lowest price for the same period was registered at $37.55 on 10/23/23.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
CRISPR Therapeutics AG (CRSP) has experienced a quarterly rise of 50.59% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.73B and boasts a workforce of 458 employees.
CRISPR Therapeutics AG: What Analysts Are Saying
As of right now, 16 analysts are rating CRISPR Therapeutics AG as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 11 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 2 analysts are rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 50.16, with a change in price of +15.02. Similarly, CRISPR Therapeutics AG recorded 1,408,256 in trading volume during the last 100 days, posting a change of +26.28%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for CRSP stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.13.
CRSP Stock Stochastic Average
Today, CRISPR Therapeutics AG’s raw stochastic average for the past 50 days stands at 89.62%, indicating a rise from the raw stochastic average of the last 20 days, which was 89.62%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 93.70% and 91.84% respectively.
CRSP Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant gain of 77.56% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 16.18%. Over the past 30 days, the price of CRSP has fallen by 81.45%. And in the last five days, it has surged by 38.78%.